使用肌肉萎缩基因治疗Elevidys, Sarepta治疗机构报告说,患者因肝损伤死亡。 Sarepta Therapeutics reports a patient death due to liver injury while using its muscular dystrophy gene therapy Elevidys.

Sarepta治疗机构报告说,在使用其基因疗法Elevidys治疗肌肉萎缩时,病人死亡。 Sarepta Therapeutics reported a patient death while using its gene therapy Elevidys for muscular dystrophy. 患者是一名年轻男子,死于急性肝损伤,这是已知的副作用,标志着与治疗有关的首次死亡。 The patient, a young man, died from acute liver injury, a known side effect, marking the first fatality linked to the therapy. Elevidis于2023年被加速批准,尽管人们对其有效性有所顾虑,但已经用于800多名患者。 Elevidys, which was expedited for approval in 2023 despite concerns about its effectiveness, has been used in over 800 patients. Sarepta计划更新治疗处方信息, 其份额下降超过23%。 Sarepta plans to update the therapy's prescribing information, and its shares fell by over 23%.